Fulcrum Therapeutics

News

Following the failure of its sickle cell programme, Fulcrum Therapeutics will merge with Slate Medicines to advance Slate's migraine therapy.

News

Company launched following $55 million series A funding round.

News

Amgen's Imdelltra and AstraZeneca's Imfinzi have improved survival compared to Imfinzi alone as first-line maintenance treatment for ES-SCLC.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.